AU
UK
CA
NZ
IND
US
Last update at 2026-06-18T23:59:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Vanguard Health Care Fund's Strategic Moves: Johnson & Johnson Takes Center Stage with 2. ...
Thu 14 Aug 25, 06:00 AMBoston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?
Fri 23 May 25, 03:30 PMWas Jim Cramer Right About Boston Scientific Corporation (BSX)?
Fri 23 May 25, 10:29 AMCiti shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
Thu 22 May 25, 01:18 PMZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues
Mon 19 May 25, 01:13 PMAbbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs
Mon 19 May 25, 11:47 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 3385.00M | 2282.00M | 1985.00M | 1141.00M | 1076.00M |
| Minority interest | 6.00M | 8.00M | 1.00M | - | - |
| Net income | 2886.00M | 1854.00M | 1593.00M | 698.00M | 1041.00M |
| Selling general administrative | 6887.00M | 5984.00M | 4974.00M | 4520.00M | 4359.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 13853.00M | 10267.00M | 8831.00M | 8679.00M | 8128.00M |
| Reconciled depreciation | 1368.00M | 1269.00M | 1177.00M | 803.00M | 741.00M |
| Ebit | - | 2669.00M | 2257.00M | 1649.00M | 2043.00M |
| Ebitda | 3733.00M | 3938.00M | 3453.00M | 2800.00M | 2784.00M |
| Depreciation and amortization | - | 1269.00M | 1196.00M | 1151.00M | 741.00M |
| Non operating income net other | - | - | - | -38.00000M | 218.00M |
| Operating income | 3971.00M | 2635.00M | 2181.00M | 1649.00M | 2043.00M |
| Other operating expenses | 16103.00M | 14112.00M | 12059.00M | 10649.00M | 10064.00M |
| Interest expense | 349.00M | 387.00M | 272.00M | 470.00M | 341.00M |
| Tax provision | 493.00M | 436.00M | 647.00M | 443.00M | 36.00M |
| Interest income | 349.00M | 107.00M | 22.00M | 470.00M | 341.00M |
| Net interest income | -320.00000M | -198.00000M | -254.00000M | -470.00000M | -341.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 376.00M | 889.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 493.00M | 436.00M | 393.00M | 443.00M | 36.00M |
| Total revenue | 20074.00M | 16747.00M | 14240.00M | 12682.00M | 11888.00M |
| Total operating expenses | 9882.00M | 7632.00M | 6650.00M | 6646.00M | 6304.00M |
| Cost of revenue | 6221.00M | 6480.00M | 5409.00M | 4003.00M | 3760.00M |
| Total other income expense net | -586.00000M | -353.00000M | -196.00000M | -508.00000M | -967.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 2892.00M | 1846.00M | 1228.00M | 698.00M | 1041.00M |
| Net income applicable to common shares | 2898.00M | 1853.00M | 1570.00M | 642.00M | 986.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 43673.00M | 39395.00M | 35136.00M | 32470.00M | 32230.00M |
| Intangible assets | 7019.00M | 6684.00M | 6003.00M | 5903.00M | 6120.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 879.00M | 1138.00M | 937.00M | 350.00M | 385.00M |
| Total liab | 19201.00M | 17392.00M | 15606.00M | 14896.00M | 15607.00M |
| Total stockholder equity | 24233.00M | 21770.00M | 19282.00M | 17574.00M | 16623.00M |
| Deferred long term liab | - | - | - | 144.00M | 310.00M |
| Other current liab | 3294.00M | 3048.00M | 2974.00M | 2701.00M | 3011.00M |
| Common stock | 17.00M | 17.00M | 17.00M | 17.00M | 17.00M |
| Capital stock | 17.00M | 17.00M | 17.00M | 17.00M | 17.00M |
| Retained earnings | 5571.00M | 2673.00M | 819.00M | -750.00000M | -1392.00000M |
| Other liab | - | - | - | 1831.00M | 2140.00M |
| Good will | 18282.00M | 17089.00M | 14387.00M | 12920.00M | 11988.00M |
| Other assets | 5077.00M | -1.00000M | 1.00M | -1.00000M | 2.00M |
| Cash | 2045.00M | 414.00M | 865.00M | 928.00M | 1925.00M |
| Cash and equivalents | 1965.00M | 414.00M | 865.00M | 928.00M | 1925.00M |
| Total current liabilities | 5439.00M | 6399.00M | 4933.00M | 3803.00M | 4274.00M |
| Current deferred revenue | 313.00M | 306.00M | 266.00M | 220.00M | 208.00M |
| Net debt | 10373.00M | 10733.00M | 8627.00M | 8354.00M | 7526.00M |
| Short term debt | 389.00M | 1778.00M | 531.00M | 20.00M | 261.00M |
| Short long term debt | 299.00M | 1778.00M | 531.00M | 20.00M | 261.00M |
| Short long term debt total | 12418.00M | 11147.00M | 9492.00M | 9282.00M | 9451.00M |
| Other stockholder equity | 19255.00M | 18805.00M | 18397.00M | 18038.00M | 17735.00M |
| Property plant equipment | 4501.00M | 3743.00M | 3298.00M | 2832.00M | 2252.00M |
| Total current assets | 8794.00M | 6920.00M | 6514.00M | 5760.00M | 6317.00M |
| Long term investments | - | 555.00M | 413.00M | 407.00M | 412.00M |
| Net tangible assets | - | - | - | 11670.00M | -1723.00000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2926.00M | 2558.00M | 2228.00M | 1970.00M | 1778.00M |
| Long term debt | 11137.00M | 8842.00M | 8566.00M | 8915.00M | 8795.00M |
| Inventory | 2944.00M | 2810.00M | 2484.00M | 1867.00M | 1610.00M |
| Accounts payable | 1144.00M | 960.00M | 942.00M | 862.00M | 794.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -610.00000M | 275.00M | 49.00M | 269.00M | 263.00M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 17.00M | 17.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | -750.00000M | -1392.00000M |
| Treasury stock | - | - | - | -2251.00000M | -2251.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 559.00M | 749.00M | 680.00M | 707.00M | 563.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 34879.00M | 32476.00M | 28622.00M | 26710.00M | 25911.00M |
| Capital lease obligations | 125.00M | 527.00M | 395.00M | 352.00M | 395.00M |
| Long term debt total | 11137.00M | 8968.00M | 8571.00M | 8915.00M | 8804.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -5687.00000M | -1704.00000M | 56.00M | 15.00M |
| Change to liabilities | - | - | - | -255.00000M | 408.00M |
| Total cashflows from investing activities | -2640.00000M | -5687.00000M | -2574.00000M | -2011.00000M | -1597.00000M |
| Net borrowings | -491.00000M | 1827.00M | -4.00000M | -165.00000M | -165.00000M |
| Total cash from financing activities | -395.00000M | 1814.00M | 5.00M | -548.00000M | -95.00000M |
| Change to operating activities | - | - | - | -209.00000M | -134.00000M |
| Net income | 2892.00M | 1846.00M | 1592.00M | 698.00M | 1041.00M |
| Change in cash | 1541.00M | -449.00000M | -82.00000M | -1042.00000M | 173.00M |
| Begin period cash flow | 606.00M | 1055.00M | 1077.00M | 2168.00M | 1995.00M |
| End period cash flow | 2147.00M | 606.00M | 995.00M | 1126.00M | 2168.00M |
| Total cash from operating activities | 4534.00M | 3435.00M | 2503.00M | 1526.00M | 1870.00M |
| Issuance of capital stock | - | - | - | 0.00000M | 0.00000M |
| Depreciation | 1368.00M | 1269.00M | 1196.00M | 1136.00M | 1093.00M |
| Other cashflows from investing activities | -171.00000M | -257.00000M | -52.00000M | -1423.00000M | -1057.00000M |
| Dividends paid | - | 0.00000M | 28.00M | -55.00000M | -55.00000M |
| Change to inventory | -188.00000M | -228.00000M | -660.00000M | -321.00000M | -346.00000M |
| Change to account receivables | -269.00000M | -351.00000M | -238.00000M | -220.00000M | -279.00000M |
| Sale purchase of stock | 282.00M | 230.00M | 182.00M | 136.00M | 110.00M |
| Other cashflows from financing activities | -186.00000M | -243.00000M | -145.00000M | 2806.00M | -150.00000M |
| Change to netincome | - | - | - | 410.00M | 100.00M |
| Capital expenditures | 876.00M | 790.00M | 800.00M | 612.00M | 554.00M |
| Change receivables | - | - | - | -220.00000M | -279.00000M |
| Cash flows other operating | - | - | - | 79.00M | -146.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | -1033.00000M | 178.00M |
| Change in working capital | -246.00000M | -462.00000M | -770.00000M | -1005.00000M | -351.00000M |
| Stock based compensation | 299.00M | 266.00M | 233.00M | 220.00M | 194.00M |
| Other non cash items | 221.00M | 516.00M | 253.00M | 540.00M | 17.00M |
| Free cash flow | 3658.00M | 2645.00M | 1703.00M | 914.00M | 1316.00M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BSX Boston Scientific Corp |
0.34 0.76% | 45.29 | 31.49 | 17.24 | 4.41 | 3.65 | 4.88 | 19.19 |
| ABT Abbott Laboratories |
-0.09 0.10% | 88.41 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| SYK Stryker Corporation |
6.66 2.21% | 307.80 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
1.20 1.54% | 79.34 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SEMHF Siemens Healthineers AG |
- -% | 39.14 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael F. Mahoney | Chairman, Pres & CEO | 1965 |
| Mr. Daniel J. Brennan | Exec. VP & CFO | 1966 |
| Mr. Joseph M. Fitzgerald | Exec. VP & Group Pres of Cardiology | 1964 |
| Mr. Jeffrey B. Mirviss | Exec. VP & Pres of Peripheral Interventions | 1966 |
| Mr. John Bradley Sorenson | Exec. VP of Global Operations | 1968 |
| Mr. Jonathan R Monson | VP, Global Controller & Chief Accounting Officer | NA |
| Ms. Jodi Euerle Eddy | Sr. VP and Chief Information & Digital Officer | 1973 |
| Ms. Susan Vissers Lisa | VP of Investor Relations | 1969 |
| Mr. Vance R. Brown | Sr. VP, Gen. Counsel & Corp. Sec. | NA |
| Ms. Catherine Jennings | VP of Global Marketing & New Bus. Devel. of Peripheral Interventions | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...